Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : WAND (Milestone Scientific) -- Ignore unavailable to you. Want to Upgrade?

To: Mason Barge who wrote (521)	5/21/1998 5:33:00 AM
From: Alex Georges	Read Replies (1) \| Respond to of 717

Serious Problem??? -give me a break- I have been reading this forum for the past several weeks and frankly I am amazed by the negative and destructive campaign against Milestone Scientific. Try as they may to manipulate the stock, these biased naysayers have yet to effect the quality of the product or the subsequent sales. I agree with Mr. Cords that this latest blurb is much ado... First of all, the story broke yesterday at 10:30 EST and yet the stock still went up 11/16 (18 1/16). What is the serious problem? The company's fine performance in both product and financial numbers is the relevant story here: I saw a demonstration here in Houston just last week. The WAND is amazing, and sure enough... 'painless'. Also, the real treasure here is in the numbers behind the disposables. It is my humble and unsolicited opinion that the company is sound financially and on the forefront of the most important medical breakthrough in the area of distribution of intramuscular drugs into the body. PS - Didn't Bloomberg just have to go through the embarrassing process of retracting another story involving Milestone that leaves the news service and its writer damaged??? Keep up the good work - Best, AJG

To: Mason Barge who wrote (521)	5/21/1998 7:50:00 AM
From: CMon	Read Replies (1) \| Respond to of 717

Mason, this shouldn't have been a surprise to you, it wasn't to me. Krochak filed to sell stock in February. He received this stock as compensation for a big investment of his time, away from his practice, on the company's behalf. One could argue that getting paid in stock is a demonstration of his belief in the product. That doesn't take more than a little faith. It takes a good dose of cynicism, however, to assume that the company's researchers accepted payment for their conclusions rather than their time. Particularly if you've had the injection, as I know you have. In which case, their conclusions are no surprise.